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Neck mass as the first presentation of metastatic prostatic adenocarcinoma
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Received December 25, 2009; accepted December 15, 2010AbstractAdenocarcinoma of the prostate (CAP) is a rare diagnosis in men younger than 50 years of age; this age group accounts for less than 0.1% of
all patients with prostatic cancer. Left supraclavicular lymphadenopathy (LSCL) as the presenting symptom of metastatic CAP is even rarer. No
cases of CAP presenting as LSCL in men younger than 45 years have been reported in the literature. Here we report a 42-year-old male with the
uncommon presentation of CAP as LSCL. In adult males with persistent LSCL, even if younger than 45 years, measurement of serum prostate
specific antigen is warranted at the time of initial presentation, and the lymph node biopsy should be subsequently stained for prostate specific
antigen immunohistochemically. These examinations are crucial to establish a definitive diagnosis of CAP and, in turn, to institute appropriate
management and achieve the best possible outcome.
Copyright  2011 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
Keywords: adenocarcinoma of prostate; digital rectal examination; lymphatic metastasis; prostate-specific antigen1. Introduction
Cervical lymph nodes are a common site of metastasis for
head and neck malignancy, and cancers originating from the
other sites can also metastasize to these nodes. Adenocarci-
noma of the prostate (CAP) is known to metastasize to
cervical nodes, and should be considered in the differential
diagnosis of neoplastic lesions of the head and neck.1,2
CAP is the most common noncutaneous human malig-
nancy, with an estimated 186,320 new cases in the USA in
2008. It is also the second-most lethal tumor among men, with
28,660 expected deaths in 2008.3 In Taiwan, CAP is the fifth-
most common cancer and the seventh-leading cause of cancer
death in men.4 It is rarely diagnosed in men younger than 50
years of age; this age group accounts for less than 0.1% of all
patients with CAP. Peak incidence of CAP occurs between the
ages of 70 and 74 years, with 85% diagnosed after the age of* Corresponding author. Dr. Yaoh-Shiang Lin, Department of Otolaryn-
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doi:10.1016/j.jcma.2011.09.01265 years.5 Age at diagnosis among men with prostate cancer
continues to fall, and the proportion of young men with
prostate cancer continues to rise as a result of the current and
evolving practices of screening and treatment. Lin et al re-
ported that men who were younger than 55 years at diagnosis
increased from 2.3% between 1988 and 1991 to 9% between
2000 and 2003, whereas the median age at diagnosis decreased
from 72 years in 1988 to 68 years in 2003.6 The incidence of
CAP metastatic to the supraclavicular lymph nodes is rare,
with a reported rate of approximately 0.28%.7 The prognosis
of metastatic CAP to the head and neck can be relatively good,
with the possibility of prolonged survival after appropriate
diagnosis and treatment.2,8,9
Review of the literature suggests that in patients with neck
masses, CAP should be ruled out if the patients are older than
45 years of age. This case report highlights the need for a high
index of suspicion of CAP in patients with neck masses, even
if they are younger than 45 years old.2. Case report
A 42-year-old healthy Taiwanese male presented with a 2-
month history of persistent, palpable, and painless masses ofhinese Medical Association. All rights reserved.
Fig. 2. Excision biopsy of the left neck masses showing a poorly differentiated
metastatic adenocarcinoma of undetermined origin, comprised of malignant
cells with vesicular nuclei and prominent nucleoli (hematoxylin and eosin
stain, original magnification 400).
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complaints, including difficult swallowing, breathing, or
bladder symptoms. His past medical and family history were
unremarkable. He had a 20-year history of smoking, drinking
alcohol and betel nut chewing.
Physical examination revealed two round, palpable, fixed,
firm and non-tender masses in the left supraclavicular fossa,
with the largest one measuring approximately 3 2cm and
the smaller one 2 1 cm. Examination of the chest and
abdomen were unremarkable. On physical examination, the
pubic and groin region, external genitalia, scrotum and testes
were unremarkable. Digital rectal examination (DRE) was not
performed at that time.
Laryngoscopy and nasopharyngoscopy showed normal
smooth mucosa of the oropharynx, hypopharynx and naso-
pharynx. X-ray of the chest and kidneyseuretersebladder
(KUB) were unremarkable. Routine blood biochemistry and
thyroid function tests were within the normal range. Urinalysis
and ultrasound imaging of the abdomen were unremarkable.
Computed tomography (CT) of the neck showed a cluster of
enlarged lymph nodes involving the left supraclavicular fossa
(Fig. 1). Fine-needle aspiration biopsy revealed small clusters
of abnormal cells with a high nucleus-to-cytoplasm ratio,
suggestive of malignancy. Rigid endoscopy of the upper aer-
odigestive tract showed normal findings. Excisional biopsy of
the left neck masses revealed poorly differentiated metastatic
adenocarcinoma of undetermined origin (Fig. 2).
Serum tumor markers were examined in an attempt to
identify the primary lesion, revealing a prostate-specific antigen
(PSA) level of 153 ng/mL (normal < 4.0 ng/mL). The pathol-
ogist was informed of the elevated PSA, and subsequent
immunohistochemical staining of the left supraclavicular lymph
nodes was positive for PSA (Fig. 3). DRE revealed a stony hardFig. 1. Computed tomography scan of neck demonstrating a cluster of enlarged
lymph nodes involving the left supraclavicular fossa, with the largest one
measuring 2 cm in short axis (arrow).prostate with grade 2 enlargement. Transrectal ultrasound-
guided needle biopsy of the prostate demonstrated adenocar-
cinoma (Gleason score 5 þ 5 ¼ 10) (Fig. 4). A bone scan
revealed multiple bony metastases. CT of the abdomen and
pelvis showed multiple lymphadenopathy in the para-aortic and
paracaval regions, bilateral common iliac chain, and bilateral
internal and external iliac chain. Hormonal therapy was initi-
ated, and the patient subsequently underwent bilateral orchi-
ectomy. Four months later, his LSCL had regressed and serum
PSA had decreased to 0.71 ng/mL. He remained without
evidence of recurrent disease 15 months after treatment.
3. Discussion
The most common sites of metastasis of CAP are regional
lymph nodes and bones, followed by lung, bladder, liver,Fig. 3. Immunohistochemical staining of the neoplastic cells from the left
supraclavicular lymph nodes, showing strong positivity for prostate-specific
antigen (PSA) (PSA stain, original magnification 400).
Fig. 4. Transrectal ultrasonographic-guided needle biopsy of prostate
demonstrating adenocarcinoma (Gleason score 5 þ 5 ¼ 10) (hematoxylin and
eosin stain, original magnification 400).
572 Y.-Y. Lin et al. / Journal of the Chinese Medical Association 74 (2011) 570e573adrenal gland and kidney. Lymphatic dissemination most
frequently involves regional lymph nodes of the retro-
peritoneum and pelvic cavity, followed by the para-aortic
lymph nodes. The reported incidence of metastases to the
supraclavicular lymph nodes in patients with CAP is 0.28%.7
CAP is rarely diagnosed in men younger than 50 years. In
this age group, the most common presentation is an asymp-
tomatic patient with abnormal DRE or elevated PSA, or
voiding difficulty. Other common presenting signs include
bone pain, hematuria, perineal pain and urinary retention.10
Serum PSA and DRE are the most commonly used tools
for prostatic cancer screening. They are relatively easy and
noninvasive procedures to perform. The American Urological
Association and the American Cancer Society recommend
offering annual PSA testing and DRE from the age of 50 years
to men with a normal risk of prostate cancer and from an earlier
age to men at high risk.11 In our case, if DRE had been included
in the initial diagnostic process, there would have been no delay
in diagnosis.
In the literature, metastatic CAP with LSCL as the first
presentation has been reported rarely and only in patients over
45 years of age.1,2,7e9,12,13 James et al12 stated that metastatic
CAP should be considered when metastatic adenocarcinoma is
discovered in the left supraclavicular lymph nodes of men older
than 45 years, and Kathleen et al9 recommended that metastatic
prostate carcinoma should be ruled out via immunoperoxidase
staining for PSA in all men older than 45 years presenting with
carcinoma of unknown primary origin in left-sided supra-
diaphragmatic lymph nodes. Jones and Anthony1 stated that
a diagnosis of cervical adenocarcinoma of unknown primary
origin should not be issued until prostatic origin has been ruled
out. It is important to distinguish carcinoma of unknown
primary origin from metastatic CAP, because of the wide
difference in treatment and prognosis. Immunohistochemical
staining for PSA could be helpful in determining a diagnosis of
CAP,1,2,7e9 but it is not absolutely specific. Some carcinoma ofsalivary gland origin, female breast carcinoma and lung cancer
can be positive for PSA stains.8,9 Serum PSA level and prostate
biopsy are indicated for establishing a definite diagnosis of
CAP in patients with metastatic lesions of the neck positive for
PSA staining.
The prognosis of metastatic CAP to the head and neck can
be relatively good, with the possibility of prolonged survival
after appropriate diagnosis and treatment.2,8,9,14 Jones and
Anthony1 presented a series of 11 CAP patients with left-sided
cervical lymph node metastases. Despite high-stage disease in
these patients, six of 11 patients were alive and well 1e101
months after diagnosis (average 25.8 at publication). The five
patients who died had an average survival of 34.4 months; the
author stated that after appropriate treatment, their outcome
was superior to those with metastatic adenocarcinoma of
nonprostatic origin, who died at an average of 2 months from
the time of diagnosis. Chitale et al12 reported two patients with
metastatic CAP and cervical lymphadenopathy; one has
remained symptom-free for 3 years at publication, and the
other has been symptom-free for 9 years. In Taiwan, Wang et al
reported three CAPs (69, 73 and 79 years of age) presenting
with LSCL and stated that hormone treatment has been shown
to be of benefit even in patients in the advanced stages.14
In conclusion, male patients with persistent LSCL should
have serum PSA level estimated at the time of initial presenta-
tion, even if they are less than 45 years of age. Subsequent
immunohistochemical stains of their lymph node biopsies for
PSA should also be performed. These are crucial to establishing
a definitive diagnosis of CAP and, in turn, to instituting appro-
priate management and achieving the best possible outcome.References
1. Jones H, Anthony PP. Metastatic prostatic carcinoma presenting as left-
sided cervical lymphadenopathy: a series of 11 cases. Histopathology
1992;21:149e54.
2. Copeland B, Clark JM, Sura A, Kilpatrick SE, Shockley W, Meredith S.
Prostate carcinoma metastatic to the cervical lymph nodes: report of two
cases and review of the literature. Am J Otol 2001;22:420e3.
3. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics,
2008. CA Cancer J Clin 2008;58:71e96.
4. Department of Health, the Executive Yuan, Taiwan, R.O.C. Cancer
registry annual report 2007. Taiwan.
5. Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, et al.
SEER cancer statistics review, 1975e2001. National Cancer Institute;
2004.
6. Lin DW, Porter M, Montgomery B. Treatment and survival outcomes in
young men diagnosed with prostate cancer: a populationebased cohort
study. Cancer 2009;115:2863e71.
7. Hematpour K, Bennett CJ, Rogers D, Head CS. Supraclavicular lymph
node: incidence of unsuspected metastatic prostate cancer. Eur Arch
Otorhinolaryngol 2006;263:872e4.
8. Hunt JL, Tomaszewski JE, Montone KT. Prostatic adenocarcinoma
metastatic to the head and neck and the workup of an unknown epithelioid
neoplasm. Head Neck 2004;26:171e8.
9. Cho KR, Epstein JI. Metastatic prostatic carcinoma to supradiaphragmatic
lymph nodes: a clinicopathologic and immunohistochemical study. Am J
Surg Pathol 1987;11:457e63.
10. Aprikian AG, Zhang ZF, Fair WR. Prostate adenocarcinoma in men
younger than 50 years: a retrospective review of 151 patients. Cancer
1994;74:1768e77.
573Y.-Y. Lin et al. / Journal of the Chinese Medical Association 74 (2011) 570e57311. Andriole GL, Crawford ED, Grubb 3rd RL, Buys SS, Chia D, Church TR,
et al. Mortality results from a randomized prostate-cancer screening trial.
N Engl J Med 2009;360:1310e9.
12. Butler JJ, Howe CD, Johnson DE. Enlargement of the supraclavicular
lymph nodes as the initial sign of prostatic carcinoma. Cancer 1971;27:
1055e63.13. Chitale SV, Harry L, Gaches CG, Ball RY. Presentation of prostatic
adenocarcinoma with cervical lymphadenopathy: two case reports and
review of the literature. Otolaryngol Head Neck Surg 2001;125:431e2.
14. Wang HJ, Chiang PH, Peng JP, Yu TJ. Presentation of prostate carcinoma
with cervical lymphadenopathy: report of three cases. Chang Gung Med J
2004;27:840e4.
